【AI详解】Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.

文献信息

一句话小结

本文综述了纳米技术在嵌合抗原受体（CAR）疗法中的应用，指出其能够克服传统方法在固体肿瘤治疗中的局限性，并可能通过改进CAR-T细胞的递送和增强其疗效来拓宽治疗途径。研究强调了快速生成CAR-T细胞的迫切需求，并提供了关于纳米颗粒作为有效载体的策略、潜在优势及未来发展方向的详细信息，旨在推动基于纳米技术的CAR-T疗法研究。

在麦伴科研 (maltsci.com) 搜索更多文献

嵌合抗原受体 · 免疫细胞 · 免疫工程 · 细胞内转运 · 纳米免疫治疗剂

摘要

嵌合抗原受体（CAR）疗法在治疗血液癌症方面取得了显著的临床疗效，并已获得FDA批准用于治疗B细胞肿瘤。然而，复杂的生产过程和在固体肿瘤中的有限成功抑制了其广泛应用，因此促使研究人员开发新的策略以克服上述障碍。在过去的十年中，纳米技术为改善癌症免疫治疗提供了可持续的策略，涉及疫苗开发和免疫调节药物的递送。纳米技术能够增强CAR-T疗法，并可能通过作为CAR-T疗法的载体或与CAR-T联合使用，更有效地抑制固体肿瘤，超越传统方法。揭示细胞机制、障碍以及可用于操纵和/或修饰细胞的潜在策略，将使纳米技术在生物制剂递送方面实现前所未有的进展。本文综述了纳米颗粒（NPs）穿越细胞的历程和障碍。随后，讨论了应对这些障碍的方法以及调制NP作为CAR-T疗法载体的策略。最后，总结了NP在CAR-T疗法中的作用及其潜在挑战。本文旨在为读者提供关于基于NP的CAR-T疗法研究的详细概述，并将这些信息提炼成易于理解的形式，以促进设计所需的基于NP的CAR-T疗法。重要性声明：嵌合抗原受体（CAR）T细胞疗法是当今免疫肿瘤学中最活跃的领域，为B细胞恶性肿瘤患者带来了巨大的益处。然而，快速而简便的CAR-T生成程序是拓宽其治疗途径的迫切需求。纳米技术已成为CAR-T生成的一种新型替代方法。据我们所知，这是第一篇深入综述，简要突出纳米技术在CAR-T疗法中的各个方面，包括将NP品牌化为有效载体的策略、其潜在优势、挑战和未来发展道路。它为读者提供了关于基于NP的CAR-T疗法研究的详细概述，研究人员将能够将这些信息提炼成易于理解的形式，以设计所需的基于纳米技术的CAR疗法。

英文摘要

Chimeric antigen receptor (CAR) therapy has achieved remarkable clinical efficacy against hematological cancers and has been approved by FDA for treatment of B-cell tumors. However, the complex manufacturing process and limited success in solid tumors hamper its widespread applications, thus prompting the development of new strategies for overcoming the abovementioned hurdles. In the last decade, nanotechnology has provided sustainable strategies for improving cancer immunotherapy through vaccine development and delivery of immunomodulatory drugs. Nanotechnology can boost CAR-T therapy and may overcome the existing challenges by emerging as a carrier for CAR-T therapy or in combination with CAR-T, it may inhibit solid tumors more effectively than conventional approaches. The revealing of cellular mechanisms, barriers and potential strategies that could be used to manipulate and/or modify cells would enable unprecedented advances in nanotechnology for biologics delivery. This review outlines the journey and barriers of nanoparticles (NPs) across the cell. Subsequently, the approaches to tackle the barriers and strategies to modulate NPs as a carrier for CAR-T therapy are discussed. Finally, the role of NPs in CAR-T therapy and the potential challenges are summarized. This review aims to provide the readers with a detailed overview of NP-based CAR-T therapy research and distil this information into an accessible form conducive to design desired CAR-T therapy using NP approach. STATEMENT OF SIGNIFICANCE: Chimeric antigen receptor (CAR) T-cell therapy is the most vibrant field in immuno-oncology today, with enormous benefits to patients with B-cell malignancies. However, a rapid and straightforward procedure for CAR-T generation is an exigent need to broaden its therapeutic avenue. Nanotechnology has emerged as a novel alternative approach for CAR-T generation. To the best of our knowledge, this is the first in-depth review that briefly highlights the various aspects of nanotechnology in CAR-T therapy, including the strategies to brand NPs as an effective carrier for CAR cargo, its potential advantages, challenges, and future roadmap. It provides readers with a detailed overview of NP-based CAR-T therapy research, and researchers would be able to distill this information into an accessible form conducive to design the desired CAR therapy using the nanotechnology approach.

麦伴智能科研服务

主要研究问题

1. 纳米技术在CAR-T疗法中具体如何提高免疫应答的效果？
2. 除了CAR-T疗法，纳米技术在其他类型的癌症免疫治疗中有哪些应用？
3. 在制造CAR-T细胞的过程中，纳米载体的使用会对细胞的活性和功能产生什么影响？
4. 目前在纳米技术与CAR-T疗法结合方面存在哪些主要挑战，未来的研究方向是什么？
5. 如何评估纳米载体在CAR-T疗法中的安全性和有效性？

核心洞察

1. 研究背景和目的

CAR-T细胞疗法是一种针对血液肿瘤（如B细胞肿瘤）取得显著临床疗效的免疫疗法，已获得FDA批准。然而，其复杂的生产过程和在实体肿瘤中的应用受限，成为了推广的主要障碍。因此，本研究旨在探讨纳米技术如何提升CAR-T疗法的效果，特别是在克服现有挑战方面的潜力。

2. 主要方法和发现

本综述详细分析了纳米颗粒（NPs）在细胞内运输的过程及其面临的障碍，并讨论了如何针对这些障碍进行策略性调整和改造，以便有效地将NPs作为CAR-T疗法的载体。研究表明，纳米技术能够通过改善疫苗开发和免疫调节药物的递送来提升癌症免疫治疗的效果。此外，纳米技术与CAR-T疗法的结合，可能在抑制实体肿瘤方面表现出优于传统方法的效果。

3. 核心结论

纳米技术在CAR-T疗法中展现出巨大的应用潜力，尤其是在解决制造复杂性和提高实体肿瘤治疗效果方面。通过对纳米颗粒的调制和优化，可以实现更高效的CAR-T细胞生成和递送。这种方法不仅能改善现有治疗手段，还可能为未来的新疗法开发提供新的思路和工具。

4. 研究意义和影响

本研究为纳米基础的CAR-T疗法提供了全面的概述，强调了纳米技术在免疫肿瘤学中的重要性。通过详细总结纳米技术在CAR-T疗法中的应用、优势、挑战及未来发展方向，研究为科学家和临床医生在设计和优化CAR-T疗法时提供了宝贵的参考。这一研究的深入，有助于推动免疫治疗领域的进步，最终使更多患者受益，特别是在实体肿瘤的治疗中实现突破。

引用本文的文献

1. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. - Huanrong Lan;Wei Zhang;Ketao Jin;Yuyao Liu;Zhen Wang - Drug delivery (2020)
2. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy. - Wei Li;Anghui Peng;Huajun Wu;Yingyao Quan;Yong Li;Ligong Lu;Min Cui - Frontiers in immunology (2020)
3. Nanomedicine-based cancer immunotherapy: recent trends and future perspectives. - Vinoth-Kumar Lakshmanan;Shlok Jindal;Gopinath Packirisamy;Shreesh Ojha;Sen Lian;Ajeet Kaushik;Abdulqadir Ismail M Abdullah Alzarooni;Yasser Abdelraouf Farahat Metwally;Sadras Panchatcharam Thyagarajan;Young Do Jung;Salem Chouaib - Cancer gene therapy (2021)
4. Nanomaterials for Biomedical Applications: Production, Characterisations, Recent Trends and Difficulties. - Mostafa Mabrouk;Diganta B Das;Zeinab A Salem;Hanan H Beherei - Molecules (Basel, Switzerland) (2021)
5. Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors. - Preethi Bala Balakrishnan;Elizabeth E Sweeney - Frontiers in immunology (2021)
6. Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. - Coral García-Fernández;Anna Saz;Cristina Fornaguera;Salvador Borrós - Cancer gene therapy (2021)
7. In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. - Tianqing Xin;Li Cheng;Chuchao Zhou;Yimeng Zhao;Zhenhua Hu;Xiaoyan Wu - Frontiers in oncology (2022)
8. Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy. - Seungyong Shin;Pyunghwajun Lee;Jieun Han;Se-Na Kim;Jaesung Lim;Dae-Hwan Park;Taejong Paik;Junhong Min;Chun Gwon Park;Wooram Park - Tissue engineering and regenerative medicine (2023)
9. Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines. - Tianyu Shi;Mengna Sun;Changchang Lu;Fanyan Meng - Frontiers in immunology (2023)
10. Theranostic applications of selenium nanomedicines against lung cancer. - Shaowei Liu;Weifeng Wei;Jinlin Wang;Tianfeng Chen - Journal of nanobiotechnology (2023)

… (22 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研